

What is claimed is:

5 ~~1. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with and inhibits the expression of a nucleic acid molecule encoding apolipoprotein B.~~

10 ~~2. The compound of claim 1 which is an antisense oligonucleotide.~~

15 ~~3. The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 17, 18, 19, 20, 21, 23, 24, 25, 27, 28, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 45, 46, 48, 49, 50, 51, 52, 53, 55, 56, 57, 58, 59, 61, 62, 63, 66, 67, 69, 71, 73, 74, 75, 76, 78, 79, 81, 82, 83, 84, 86, 87, 88, 90, 93, 96, 101, 101, 102, 103, 105, 109, 111, 111, 114, 115, 116, 117, 118, 119, 120, 121 or 122.~~

25 ~~4. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.~~

5. The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

30 ~~6. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.~~

35 ~~7. The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.~~

T01080" E0002660

8. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9. The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

10 11. A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding apolipoprotein B.

15 12. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

20 13. The composition of claim 12 further comprising a colloidal dispersion system.

25 14. The composition of claim 12 wherein the compound is an antisense oligonucleotide.

30 15. A method of inhibiting the expression of apolipoprotein B in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of apolipoprotein B is inhibited.

35 16. A method of treating an animal having a disease or condition associated with apolipoprotein B comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of apolipoprotein B is inhibited.

40 17. The method of claim 16 wherein the condition involves abnormal lipid metabolism.

09920033-080101

18. The method of claim 16 wherein the condition involves abnormal cholesterol metabolism.

19. The method of claim 16 wherein the condition is
5 atherosclerosis.

20. The compound of claim 1 targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with and inhibits the expression of
10 the long form of a nucleic acid molecule encoding apolipoprotein B, ApoB-100.

09920033.080101
T0T080" EEO02660